

- Group 2:** Claims 1-8, 11, 22-25, and 28, drawn to methods of administering compounds with identical or similar effects as SEQ ID NO:2 or 4, to the extent that the claims encompass administration of products of undefined structure;
- Group 3:** Claims 14-16, 31-33, 40, and 52-60 drawn to compounds of undefined structure with identical or similar effects as SEQ ID NO:2 or 4;
- Group 4:** Claims 53-65, drawn to compounds that are related by sequence identity to SEQ ID NO:2;
- Group 5:** Claims 17 and 20-21, drawn to methods comprising administering a GIP antagonist of undefined structure;
- Group 6:** Claims 18 and 46-47, drawn to methods comprising administering an antibody;
- Group 7:** Claims 19 and 48-49, drawn to methods comprising administering a GIP receptor antagonist;
- Group 8:** Claims 34-35, drawn to methods of administering compounds of undefined structure;
- Group 9:** Claims 36 and 39, drawn to a method comprising administering to a subject a pharmaceutical composition comprising a GIP antagonist of undefined structure;
- Group 10:** Claims 37 and 50, drawn to methods of administering an antibody to GIP;
- Group 11:** Claims 38 and 51, drawn to methods of administering an antagonist of a GIP receptor of undefined structure;
- Group 12:** Claim 41, drawn to a method comprising providing a compound for a manufacture of a pharmaceutical composition; and
- Group 13:** Claims 42-45, drawn to methods of determining an abnormal GIP level.

Applicants hereby elect the invention of Group 1, claims 1-13 and 22-30, without traverse.

**Conclusion**

It is believed that this paper is fully responsive to the outstanding requirement for claim election. Accordingly, consideration of these remarks is respectfully requested.

Dated: April 19, 2007

Respectfully submitted,

By 

Paul M. Zagar

Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant